Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Ariel Messman-Rucker is an Oakland-born journalist who now calls the Pacific Northwest her home. When she’s not writing about politics and queer pop culture, she can be found reading, hiking, or ...